Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease
The Pharma Data
NOVEMBER 6, 2020
The Advisory Committee also voted 0 yes, 7 no and 4 uncertain on the question, “Does Study 103 (PRIME) provide supportive evidence of the effectiveness of aducanumab for the treatment of Alzheimer’s disease?”, Aducanumab (BIIB037) is an investigational human monoclonal antibody studied for the treatment of Alzheimer’s disease.
Let's personalize your content